Pfenex (Pfenex) Cash-to-Debt : 18.33 (As of Jun. 2020)

View and export this data going back to 2014. Start your Free Trial

What is Pfenex Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pfenex's cash to debt ratio for the quarter that ended in Jun. 2020 was 18.33.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pfenex could pay off its debt using the cash in hand for the quarter that ended in Jun. 2020.

The historical rank and industry rank for Pfenex's Cash-to-Debt or its related term are showing as below:

PFNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.03 Med: 65.46 Max: No Debt
Current: 18.33

During the past 8 years, Pfenex's highest Cash to Debt Ratio was No Debt. The lowest was 1.03. And the median was 65.46.

PFNX's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.5 vs PFNX: 18.33

Pfenex Cash-to-Debt Historical Data

The historical data trend for Pfenex's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pfenex Cash-to-Debt Chart

Pfenex Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

27.84

1,018.76

89.13

110.89

14.46

Pfenex Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Cash-to-Debt	Get a 7-Day Free Trial															110.40	109.12	14.46	18.31	18.33

Competitive Comparison of Pfenex's Cash-to-Debt

For the Biotechnology subindustry, Pfenex's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfenex's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pfenex's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pfenex's Cash-to-Debt falls into.

Pfenex Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pfenex's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	55.624	/	(0.951	+	2.896)
	=	14.46

Pfenex's Cash to Debt Ratio for the quarter that ended in Jun. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	61.036	/	(0.834	+	2.496)
	=	18.33

Pfenex (AMEX:PFNX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pfenex Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pfenex's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfenex (Pfenex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pfenex Inc (AMEX:PFNX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10790 Roselle Street, San Diego, CA, USA, 92121

Website

https://www.pfenex.com

Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.

Executives

Ligand Pharmaceuticals Inc	10 percent owner	3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Jason Grenfell-gardner	director	105 LINCOLN AVENUE BUENA NJ 08310
Patrick K. Lucy	officer: Chief Business Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Robin Campbell	director	C/O PFENEX INC., 10790 ROSELLE STREET SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Mack Taylor	director	C/O PFENEX, INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Evert B. Schimmelpennink	director, officer: See Remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Shawn Scranton	officer: Chief Operating Officer	C/O PFENEX INC 10790 ROSELLE STREET SAN DIEGO CA 92121
Martin Brenner	officer: Chief Scientific Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Lorianne Masuoka	director	C/O PFENEX INC. 10790 ROSELLE STREET SAN DIEGO CA 92121
Newtyn Management, Llc	10 percent owner	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Weiss Asset Management Lp	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc	10 percent owner	222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116